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Ku70/80 nonhomologous end-joining activity is essen-
tial for resolving random DNA double-strand breaks,
and the Ku70/80 protein complex has been proposed as
‘‘caretaker’’ of genomic stability.We studied the Ku70/80
heterodimer activity in a patient a¡ected by multiple
basal cell carcinomas with a personal history of moder-
ate exposure to ionizing radiation. The Ku70/80 DNA-
binding activity was analyzed, by electrophoretic mo-
bility shift assay, in ¢ve tumor biopsies from di¡erent
sites and at distinct clinical stages, and in three matched
normal skin samples from the same patient. As control
normal tissues from healthy individuals were also
tested. The ¢ve basal cell carcinomas were classi¢ed as
‘‘non aggressive’’ and ‘‘aggressive’’ on the basis of mor-
phologic parameters and expression of the molecular
markers bcl-2, Ki67/MIB1, and p53. A 62% increase in
the Ku70/80 DNA-binding activity was found in nor-
mal skin from the patient, compared to unexposed in-
dividuals (po0.0001). The nuclear activity of the
heterodimer was further increased in nonaggressive ba-
sal cell carcinomas compared to both matched normal
skin from the patient (31%, p¼ 0.0001) and tissues from
healthy controls (73%, p¼ 0.0001). Strikingly, the two
aggressive basal cell carcinomas tested showed very
low Ku70/80 DNA-binding activity with a reduction of
87% compared to normal skin from the patient
(po0.0001) and 64% compared to controls (p¼ 0.001).
Although these results are limited to only one patient,
together with other recent studies they support the hy-
pothesis that downregulation of the nonhomologous
end-joining pathway may be associated with tumor
progression. Key words: caretaker activity/DNA double-
strand break repair/Ku70/80 heterodimer/tumor progression.
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C
ancer is a multistep process characterized by the ac-
cumulation of multiple genetic alterations involving
oncogenes and tumor suppressor genes, in the evo-
lution from a normal cell to a malignant phenotype
(Fearon and Vogelstein, 1990). Most of the tumor
suppressor genes can be divided into two categories: ‘‘gatekeeper’’
and ‘‘caretaker’’. Gatekeeper genes inhibit the cell cycle and pro-
mote cell death, whereas caretaker genes act indirectly monitor-
ing the stability of the genome and suppressing chromosomal
translocation. Inactivation of caretakers leads to genetic instability
that promotes growth by causing an increased mutation rate
(Kinzler and Vogelstein, 1997).
A caretaker role has recently been proposed for the nonhomo-
logous end-joining (NHEJ) pathway of DNA repair (Di¢lippan-
tonio et al, 2000; Ferguson et al, 2000; Gao et al, 2000). This
mechanism is critical for resolving DNA double-strand breaks
(DSB), which if left unrepaired lead to broken chromosomes
and cell death, but if repaired improperly can lead to genomic
instability and oncogenic rearrangement (Chu, 1997; Khanna
and Jackson, 2001). This mechanism of DNA repair is mediated
by the DNA-binding activity of the Ku70/80 heterodimer, the
regulatory subunit of the DNA-dependent protein kinase
(DNA-PK) (Jin andWeaver, 1997). In murine models, cells de¢-
cient for Ku80 or Ku70 display a marked increase in chromoso-
mal aberrations (Di¢lippantonio et al, 2000; Roth and Gellert,
2000). Moreover genomic instability and development of B cell
lymphoma were reported in two lines of mice lacking both the
NHEJ protein Ku80 and the p53 gene, supporting the hypothesis
of a possible role as caretaker for the NHEJ proteins (Lim et al,
2000; Roth and Gellert, 2000).
DSB can be caused by both endogenous and exogenous agents.
Oxidative metabolism generates free radicals that may cause
strand breaks and DSB are also generated as a consequence of
the V(D)J recombination, during the rearrangement of genes for
the immunoglobulins and T cell receptors (Smider and Chu,
1997), whereas the main exogenous mechanism responsible for
DSB is exposure to ionizing radiation (Chu, 1997).
Nonmelanoma skin cancers, including basal cell carcinoma
(BCC) and squamous cell carcinoma (SCC), are among the
tumors associated with exposure to ionizing radiation (Karagas
et al, 1996; Lichter et al, 2000). The risk of BCC and SCC devel-
opment is strongly increased after ionizing radiation therapies or
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X-ray exposure (Karagas et al, 1996; Lichter et al, 2000), and these
malignancies have been described in individuals exposed to the
atomic bombing of Hiroshima and Nagasaki (Ron et al, 1998).
However, the relationship between DNA DSB repair and risk
for skin cancer is not fully understood (Grossman and Wie,
1995; Gottlober et al, 1999).
In this study, we have analyzed the Ku70/80 DNA-binding
activity in skin tumor biopsies and matched normal skin from a
patient a¡ected by multiple BCC and with a personal history
of moderate exposure to ionizing radiation. As control, normal
tissues from healthy individuals were also tested. We found a
striking correlation between Ku70/80 DNA-binding activity and
tumor progression.
MATERIALS AND METHODS
The study was carefully examined by the Ethical Committee of the
Campus Bio-Medico University. The patient is a 75-y-old white male, skin
type III (Fitzpatrick classi¢cation) (DeVita et al, 1997), who developed mul-
tiple BCC, a single SCC, and aplastic anemia during the period from 1986
to 1999. The patient worked as a radiologist for 6 y, from 1955 to 1961. In
1986 he lived in Budapest from the week preceding until 2 wk following
the Chernobyl accident. No data are available about the radiation exposure
rate for our patient.The 1988 Report of the United Nations Scienti¢c Com-
mittee on the E¡ects of Atomic Radiations (UNSCEAR) (UNSCEAR
Report, 1988), however, indicates in the region of Budapest an outdoor ef-
fective dose equivalent in the ¢rst month from external irradiation of
100 mSv. The patient developed the ¢rst BCC on the forehead and then an-
other 11BCCwere diagnosed. He was last seen in our clinical facility in 1999.
The SCC and nine of the 12 BCC were excised. The patient denies previous
neoplastic pathologies and radiation therapy. Absence of palmar pits, man-
dibular cysts, calci¢cation of the falx cerebri, bi¢d ribs, and a negative family
history exclude the nevoid BCC syndrome (Gailani and Bale, 1997).
Samples Five BCC and two matched normal skin biopsies (Table I),
surgically excised at the Plastic Surgery Division of Campus Bio-Medico
University, were analyzed in this study. As controls, ¢ve normal skin
sections from healthy subjects together with one normal sample from
human bladder and three breast tissues were also tested. Informed consent
was obtained from all the subjects included in the study. All specimens
underwent histologic examination to con¢rm the diagnosis. Tumor
samples were classi¢ed morphologically on the basis of growth pattern, as
described previously (Jacobs et al, 1982; Rippey and Rippey, 1997).
PCR-based microsatellite analyses To exclude that the patient was
a¡ected by nevoid BCC syndrome, DNA extracted from fresh frozen
tumor samples and blood lymphocytes was analyzed for loss of
heterozygosity in microsatellite markers mapping on chromosome 9q
near the nevoid BCC syndrome locus (Wicking et al, 1994). The following
markers were tested: D9S196 (9q22); D9S197 (9q22.1); D9S180, D9S12,
D9S287 (9q22,3); D9S109, D9S127 (9q31) (Farndon et al, 1992; Goldstein
et al, 1994; Wicking et al, 1994). PCR conditions included a denaturation
step for 2 min at 951C, followed by 35 cycles at 951C for 1 min, 54^581C
for 1 min, 721C for 1 min, and by a ¢nal 4 min extension at 721C (Seripa
et al, 2001). About one-quarter of the PCR product was separated on a 7%
urea formamide polyacrylamide gel and exposed to ¢lm (Parrella et al, 2001).
Preparation of cell and nuclear extracts Following surgical resection,
tissue samples were immediately processed for protein extraction,
according to the Dignam method (Dignam et al, 1983]) previously
described by Pucci et al (2001). Brie£y, samples (0.1^0.5 g in weight) were
put on ice and mechanically fractionated to obtain a cellular suspension.
Red blood cells were depleted by osmotic lysis. Cells were then washed
twice and suspended in 0.5 ml of ice-cold bu¡er A (HEPESKOH
10 mM, pH 7.9, MgCl2 1.5 mM, KCl 10 mM, ethylenediamine tetraacetic
acid (EDTA) 1 mM, and dithiothreitol (DTT) 1 mM, phenyl-
methylsulfonyl £uoride (PMSF) 1 mM, NaF 20 mM, Na4P2O7 1 mM
added just prior to use); cells were allowed to swell on ice for 20 min and
then 25 mL of Nonidet P-40 10% (Fluka-Sigma, St Louis, MO) was added.
The homogenate was centrifuged for 30 s in a microfuge at 5000 oxg (the
postnuclear extract containing cytoplasmic proteins was carefully removed
and stored at 801C).The nuclear pellet was resuspended in ice-cold NaCl
extraction bu¡er (HEPESKOH 20 mM, pH 7.9, NaCl 420 mM, MgCl2
1.5 mM, EDTA 1mM, glycerol 25%, and DTT 1mM, PMSF 1mM, NaF
20 mM, Na4P2O7 1 mM added just prior to use) and incubated on ice for
30 min. Cellular debris was removed by centrifugation for 5 min in a
microfuge at 10,000 rpm.The supernatant fraction, containing DNA-
binding proteins, was stored at ^801C. All steps of protein extraction
were checked by optical microscope. Protein content in the nuclear
extracts was determined in triplicate by Bradford assay (Bio-Rad Protein
Assay, Bio-Rad Laboratories, Munchen, Germany).
DNA end binding (mobility shift gel electrophoresis assay) All the
nuclear extracts were analyzed by electrophoretic mobility shift assay
(Zhang and Yaneva, 1992). A 32P-end labeled 56 bp DNA probe (Frasca et
al, 1998) was incubated with nuclear extracts for 30 min at room
temperature in binding bu¡er (10 mM TrisHCl pH 8, EDTA 0.5 mM,
NaCl 150 mM, DTT 1 mM, PMSF 1 mM, glycerol 10%); brie£y, the
DNA-binding reactions contained the labeled probe (50,000 cpm), nuclear
(2 mg) extracts, and closed circular plasmid DNA pUC-19 (1 mg), as
unspeci¢c competitor. For each sample three single shift assays were
performed. To normalize all the samples, an electrophoretic mobility shift
assay was performed incubating the nuclear extracts (2 mg) with 50,000
cpm per sample of 32P-end labeled Sp-1 oligonucleotide (Promega,
Madison, WI) in binding bu¡er (glycerol 20%, MgCl2 5 mM, EDTA
2.5 mM, NaCl 250 mM, TrisHCl pH 7.5 50 mM, DTT 2.5 mM) with
1 mg of poly[dI-dC] as unspeci¢c competitor. The correction factor (CF)
was calculated as follows:
Sp-1 binding activity in the sample
mean Sp-1 binding activity
and datawere normalized using the formula
MeanKu70=80 binding activity
CF
For gel supershift experiments goat polyclonal anti-Ku70 and anti-Ku86
antibodies (Santa Cruz Biotechnologies, Santa Cruz, CA) were incubated
with protein extracts for 30 min at room temperature, before adding the
other components of the binding reaction. Complexes were separated on
6% nondenaturing polyacrylamide gels, in TBE (45 mM Tris-borate, 1
mM EDTA, pH 8.0) at 200 V for 2 h 30 min.Gels were dried and exposed
to X-ray ¢lm (Amersham-Pharmacia Biotech, Buckinghamshire, UK)
overnight at 801C. The optical densities were obtained by scanning
densitometry using colon carcinoma cell line CaCo2 (ATCC) as internal
control (optical density¼ 5.4170.71).
Western blotting Protein extracts (10 mg) were boiled in sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) loading
bu¡er and separated by 10% SDS-PAGE. Proteins were transferred to a
polyvinylidene £uoride membrane (Hybond-P, Amersham-Pharmacia
Biotech) using an electroblotting apparatus and incubated for 1 h at room
temperature with 1% bovine serum albumin (BSA), 1% skim milk (Difco
Laboratory, Detroit, MI), and 0.5% Tween-20 (USB, Cleveland, OH).
Table I. Clinical characteristics and immunohistochemical results of multiple BCCs (T1^T5) from the same patient
Code Histologic subtypea Site Onset Size (cm) p53 (%)b Ki-67 bcl-2
c
T1 Nodular Forehead 0.5 62 28 n.d.
T2 Nodular Left leg Primary 0.5 55 27 þ
T3 Super¢cial Left leg 0.8 57 31 þ þ þ
T4 In¢ltrative Right leg Recurrent 1.05 74 64 Neg
T5 Micronodular Back Primary 1 91 59 Neg
aBBCs were discriminated by histological growth patterns according to Rippey and colleagues (Rippey et al, 1998).
bPercent values of positively stained cells.
cn.d., not detected.
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Membranes were stained with Poinceau S dye, to check for equal loading
and homogeneous transfer. Primary antibodies (goat polyclonal IgG anti-
Ku70 or Ku86, Santa Cruz Biotechnologies) were diluted 1:500 in 1% BSA
and incubated for 1 h at room temperature; samples were washed
extensively with 0.5% Tween-20, and diluted 1:8000 secondary anti-
body (antigoat horseradish peroxidase conjugated IgG, Santa Cruz
Biotechnologies) was added in 1% BSA, 1% milk, 0.5% Tween-20, for 1
h at room temperature. Filters were reprobed with anti-b-actin (Sigma-
Aldrich, St Louis, MO) mouse IgG1 monoclonal antibody, to normalize
the nuclear protein levels. Filters were washed and developed using an
enhanced chemiluminescence system (ECL, Amersham-Pharmacia
Biotech, Pharmacia Biotech).
Immunohistochemistry The specimens were ¢xed in 10% neutral-
bu¡ered formaldehyde and embedded in para⁄n. Based on an initial
review of all available hematoxylin and eosin stained slides of the surgical
specimen sections, we selected one representative para⁄n block from
each case for further study. Consecutive 3 mm sections were re-cut from
each study block; these sections were immunoassayed for p53, MIB1
(Ki67), bcl-2, Ku86, Ku70, and DNA protein kinase catalytic subunit
(DNA-PKcs). Immunohistochemical staining was performed by the
streptavidinbiotin method. In brief, sections were de-para⁄nized and
microwave-treated at 500 W for 5 min twice in 10 mM sodium citrate
(pH 6.0). Endogenous peroxidase in the sections was blocked by
incubating them in 0.03% hydrogen peroxide in absolute methanol for
30 min at room temperature. The antibodies used were monoclonal
mouse antibodies against human p53 protein (D07, Dakopatts, Glastrup,
Denmark) in a 1:50 dilution, human bcl-2 protein (Dakopatts) in a 1:40
dilution, and anti-Ki67 protein (MIB1 clone, Dakopatts) in a 1:50 dilution;
and goat polyclonal rabbit antibodies against Ku86 (M-20, Santa Cruz
Biotechnology) and Ku70 proteins (M-19, Santa Cruz Biotechnology) in
a 1:200 dilution and anti-DNA-PKcs protein (C-19, Santa Cruz
Biotechnology) in a 1:100 dilution. All primary antibodies were incubated
at room temperature for 2 h. After washing three times with Tris-bu¡ered
saline (TBS), sections treated with anti-p53, bcl-2, and Ki67 were incubated
with biotinylated goat antimouse/rabbit IgG (Dako) and sections treated
with anti-Ku70, Ku86, and DNA-PKcs were incubated with biotinylated
swine antigoat/mouse/rabbit IgG (Dako). They were then washed three
times with TBS, treated with streptavidin peroxidase reagent (Dakopatts)
for 10 min, and washed with TBS three times again. Finally, specimens
were incubated in diaminobenzidine for 5 min, followed by hematoxylin
counterstaining. Sections were examined under a two-head microscope by
two pathologists unaware of the clinical data and molecular results.
Statistical analysis All values provided in the text and ¢gures are means
of three independent experiments7standard deviations (SD). Mean values
were compared using the two-tailed t test. Di¡erences were considered
statistically signi¢cant for po0.05.
RESULTS
We determined the Ku70/80 DNA-binding activity in a patient
with multiple BCC. Although the patient did not show clinical
or radiologic signs of nevoid BCC syndrome (Gailani and Bale,
1997), we further excluded this possibility by analyzing DNA ex-
tracted from skin tumor biopsies and matched blood lympho-
cytes by microsatellite analysis. None of the seven markers
(Wicking et al, 1994) located on chromosome 9q in the PTCH
gene locus showed loss of heterozygosity (data not shown).
The ¢ve BCC obtained from the patient were classi¢ed as ‘‘no
aggressive’’ (T1, T2, T3) and ‘‘aggressive’’ (T4, T5) on the basis of
histologic growth patterns (Rippey, 1998) and expression of bcl-
2, p53, and Ki67/MIB1 markers (Abdelsayed et al, 2000; Ramdial
et al, 2000) (Fig 1,Table I). As expected, bcl-2 immunostaining
was present in the nonaggressive tumors but not in the aggressive
BCC, whereas Ki67/MIB1 expression was 50% lower in the no
aggressive tumors compared with the aggressive BCC. p53 ex-
pression did not show signi¢cant di¡erences between the two
groups (Fig 1,Table I).
The Ku70/80 DNA-binding activity was determined in the
¢ve BCC (T1T5) and matched normal skin samples (Sk1, Sk2)
from the patient (Fig 2A,Table II). As control, the activity was
also tested in normal skin (C1C5), bladder mucosa, and
mammary gland (C6C9) from healthy individuals (Fig 2A,
Table II).The speci¢city of the Ku70/80-binding activity was ob-
tained by addition of goat polyclonal anti-Ku70 and anti-Ku86
antibodies, which demonstrated the supershift of the DNA end
binding activity from the extracts (Fig 2B). All of the bands cor-
responding to the Ku DNA-binding activity in the samples were
normalized for Sp-1 DNA-binding activity, as described in Mate-
rials and Methods (Table II).
No statistically signi¢cant di¡erences in the Ku70/80 DNA-
binding activity were detected among the control groups
(C1C5 vs C6C9: p40.1). Normal skin samples from the
patient showed a 62% increase in the Ku70/80 DNA-binding
activity compared to tissues from healthy controls (po0.0001)
(Table III). In the three no aggressive BCC a further increase
in the heterodimer binding activity could be demonstrated
compared to tissues from healthy controls (p¼ 0.0001) and
matched normal skin from the patient (p¼ 0.001) (Table III),
whereas the two aggressive BCC showed a dramatic decrease in
the Ku70/80 DNA-binding activity with a reduction of 64%
Figure1. Expression of p53, Ki67-MIB1, and bcl-2 in two BCC.Tissue sections from super¢cial (T3) and in¢ltrative (T4) tumors from the patient are
shown as examples for the di¡erential expression of p53, Ki67, and bcl-2 proteins. Positive nuclear staining for p53 is evident in both nonaggressive and
aggressive BCC but it is absent from the surrounding normal skin. In the super¢cial tumor (T3) many nuclei do not express Ki67.The pattern of expression
for bcl-2 is exclusively cytoplasmic in the epithelial cells. There is no detectable staining for bcl-2 in the in¢ltrative (T4) tumor. Arrows: positively stained
lymphocytes are shown as control. Magni¢cation: 400 .
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compared to controls (p¼ 0.001) and 87% compared to normal
skin from the patient (po0.0001) (Table III).
To determine whether di¡erences in DNA-binding activity
were due to changes in protein expression, Ku70, Ku86, and
DNA-PKcs protein levels were determined by immunohisto-
chemical assay (Table III, Fig 3) and western blot analysis in nu-
clear extracts from patient tissues (Fig 2C). Surprisingly, no
signi¢cant changes in protein expression were detected in the
two tumors with decreased Ku70/80 DNA-binding activity
tested, suggesting that proteins are expressed but not functional
(Table III, Figs 2C, 3).
DISCUSSION
Upregulation of the Ku70 and Ku80 subunits following ionizing
radiation exposure has been reported previously (Featherstone
and Jackson, 1999; Brown et al, 2000). In this study we tested
the Ku70/80 DNA-binding activity and protein expression in a
patient who developed multiple BCC, and with a personal
history of moderate radiation exposure. As control, the heterodi-
mer binding activity was also determined on tissues from
healthy controls. The ¢rst interesting point is the increase in the
Ku70/80 DNA-binding activity in normal skin from the
patient compared to healthy controls, suggesting a baseline
activation of the NHEJ DNA repair pathway in the skin of this
individual.When the Ku70/80 DNA-binding activity was tested
on the ¢ve BCC we found two di¡erent behaviors. In three of
the tumors the heterodimer DNA-binding activity was in-
creased compared to matched skin and controls, whereas
the remaining two tumors displayed a dramatic decrease of the
activity.
We correlated our results with the morphologic and molecular
characteristics of the ¢ve tumors. BCC generally show a favorable
clinical behavior, but a percentage of them grow aggressively,
in¢ltrating contiguous structures. A number of authors have
Figure 2. (a) Ku70/80 DNA-binding activity and protein expression in normal and tumor samples. Representative results of the electrophoretic
mobility shift assay of proteinDNA complexes are shown. Arrows indicate free probe and speci¢c proteinDNA complexes. From left to right: Sk1, Sk2,
normal skin samples from the patient; T1T5, nuclear extracts from ¢ve di¡erent BCC from the patient; CaCo, CaCo2 cell line protein extract (HTB 37,
ATCC); C1C5, normal skin samples from healthy individuals; p, free probe without protein extract; C6C9, bladder mucosa and mammary gland from
healthy individuals. (b) Supershift experiments. From left to right: lane 1, protein extract from normal skin without antibodies; lane 2, polyclonal anti-Ku70
antibody incubated with protein extract from normal skin; lane 3, anti-Ku86 antibodies incubated with nuclear extracts from normal skin sample; p, free
probe. (c) Western blot analysis of p70 and p80 expression. Sk1, normal skin from the patient; T1T4, BCC from the patient. The upper panel shows results
from experiment 1; the exposure time allows the detection of the Ku80 protein only for the T4 tumor. (arrow) The lower panel shows results from experi-
ment 2; a longer exposure time allows the detection of both Ku70 and Ku80 proteins.
Table II. Ku70/ku80 DNA binding activity and SP1 normalization
KU70/80 binding SP1-bindinga
Exp. 1 Exp. 2 Exp. 3 Mean7SD Exp. 4 CFb Normalized values
C1 1.00 1.20 0.44 0.8870.40 3.50 0.84 1.04
C2 1.20 1.50 1.78 1.4970.29 4.00 0.97 1.55
Normal skin C3 0.92 1.30 0.16 0.7970.58 3.40 0.82 0.97
C4 1.56 2.00 2.22 1.9370.34 5.00 1.21 1.60
C5 2.03 1.54 1.80 1.7970.25 4.00 0.97 1.86
C6 1.20 0.85 1.61 1.2270.38 4.40 1.06 1.15
C7 2.60 1.74 1.91 2.0870.46 4.40 1.06 1.97
Controls C8 1.58 2.10 2.94 2.2170.69 3.90 0.94 2.35
C9 2.10 1.40 1.70 1.7370.35 4.00 0.96 1.80
SK1 3.50 3.80 2.43 3.2470.72 4.00 0.97 3.37
SK2 4.00 4.69 4.25 4.3170.35 4.50 1.09 3.98
T1 5.50 5.80 3.87 5.0671.04 4.50 1.09 4.67
Patient T2 5.00 6.09 4.85 5.3170.68 4.00 0.97 5.52
T3 5.40 6.00 5.94 5.7870.33 4.20 1.01 5.72
T4 1.00 0.80 0.48 0.7670.26 4.00 0.97 0.79
T5 0.45 0.10 0.00 0.1870.24 3.80 0.92 0.20
aThe mean value for the SP1 binding activity was 4.1470.44;
bC.F., correction factor.
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adopted a histopathologic classi¢cation of BCC based on tumor
growth patterns that identify four possible classes: nodular, in¢l-
trative, super¢cial, and mixed (Rippey, 1998; Milroy et al, 2000).
In¢ltrative and micronodular tumors are more likely to be in-
completely excised; thus they recur more frequently and are con-
sidered as aggressive. A role as prognostic factor in BCC has been
proposed for bcl-2 and p53. bcl-2 expression was directly corre-
lated with nonaggressive BCC and a favorable clinical follow-up,
whereas the expression of p53 was correlated with the aggressive
histotypes (Barrett et al, 1997; Ramdial et al, 2000; Staibano et al,
2001). Moreover the expression of the proliferation marker Ki67/
MIB1 also directly correlates with aggressiveness (Healy et al,
1995). Strikingly, the two tumors with a decrease in Ku70/80
binding activity showed all the characteristics of aggressive tu-
mors, whereas the three BCC with high heterodimer binding
activity displayed the characteristics of a no aggressive phenotype
(Table I).
Our data on normal skin and nonaggressive BCC seem to
support the hypothesis that the increase of Ku70/80 DNA-
binding activity represents a physiologic mechanism, attempting
to prevent or reduce the development of genomic instability.
It is more di⁄cult to explain the decrease in heterodimer binding
activity in the aggressive BCC.This might be due to post-transla-
tional regulation, or alternatively to mutation or allele inactiva-
tion in one or more of the elements involved in the NHEJ
pathway. Unfortunately we did not have enough material to per-
form mutational and expression analysis on the Ku70 and Ku80
genes to further investigate this issue. In both cases, however, we
can speculate that the failure of the NHEJ pathway may be
responsible for genetic instability and lead ultimately to tumor
progression.
In animal models the inactivation of the NHEJ pathway in-
creases the tumorigenic e¡ect determined by loss of function of
the p53 protein (Di¢lippantonio et al, 2000; Gao et al, 2000;
Table III. Ku70/80 DNA-binding activity and protein expression in control skin specimens (C1^C5), normal skin (Sk1^Sk2) and













C1^C5 Normal skin 62 42 45 1.470.4 
Sk1 Normal skin 70 61 60 3.770.4 (Po0.0001)c
Sk2 72 55 62
T1 No aggressive 73 54 59 5.370.5 (Po0.0001)d
T2 72 61 66 (P¼ 0.001)e
T3 68 70 85
T4 Aggressive 97 63 62 0.570.4 (Po0.001)d
T5 95 62 69 (Po0.0001)e
aPercent values of positively stained cells.
bOptical densities obtained from the densitometric analysis of the bands corresponding to the speci¢c DNA-binding activity, in mobility-shift assays; values are means
7standard deviations of three independent experiments.
cPatient normal skin vs C1^C5 (Student’s T-test).
dTumors vs C1^C5 (Student’s T-test).
eTumors vs Sk1^Sk2 (Student’s T-test).
Figure 3. Nuclear expression of Ku70,
Ku86, and DNA-PKcs in no aggressive
(T2) and aggressive (T4, T5) tumors.
Representative results of para⁄n sections
stained with antibodies against Ku70,
Ku86, and DNA-PKcs. Ku86 immunos-
taining is weaker than for Ku70 for all the
tumors tested. There are no signi¢cant dif-
ferences in protein expression between the
two aggressive BCC (T4,T5) compared to
the nonaggressive BCC. Magni¢cation:
400 .
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Khanna and Jackson, 2001). Interestingly, in our patient p53 is
overexpressed in all ¢ve BCC, but only in the two aggressive
tumors did we also ¢nd an inactivation of the NHEJ pathway.
In fact, in physiologic conditions the p53 protein is rapidly
degraded through interaction with the MDM2 gene product
and it is not detected by immunohistochemical staining. p53
overexpression occurs in the presence of mutations that cause
disruption of the p53^MDM2 interaction leading to elevated le-
vels of an inactive p53 protein (Umekita et al, 1994; Prives and
Hall, 1999).
It remains to be determined whether the di¡erential modula-
tion of the NHEJ pathway is a common event in aggressive and
nonaggressive tumors. Previous studies reported a downregula-
tion of the Ku70/80 NHEJ components in aggressive and meta-
static malignancies compared to benign lesions or less aggressive
tumors of the same types (Pucci et al, 2001; Rigas et al, 2001). If
further studies con¢rm the di¡erential modulation of the Ku70/
80DNA-PKcs complex during tumor progression, the role of
the NHEJ pathway as caretaker would be proven (Ferguson et al,
2000; Gao et al, 2000) and we would have a new and potentially
powerful marker of prognosis.
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